Shipments of Johnson & Johnson ναccιnє halted
Published: April 1, 2021Share
| Print This
Source: the hill
Future shipments of the Johnson & Johnson CÖVÌD-19 ναccιnє have been halted while the Food and Drug Administration investigates after human error at a manufacturing plant ruined 15 million doses, The New York Times reported Wednesday
The plant in Baltimore is run by Emergent Biosolutions, and workers mixed up the ingredients in the ναccιnє, the Times reported.
The error does not affect doses of the Johnson & Johnson ναccιnє that have already been distributed, as they were made in the Netherlands, but it impacts future shipments of the ναccιnє, according to the Times.
The Johnson & Johnson ναccιnє is one of three being used in the United States.
The pfιzєr and mσdernα ναccιnєs were already the bulk of the U.S. supply, and those are proceeding as planned. But the error could limit the ability of Johnson & Johnson to add considerably to the U.S. supply in the coming weeks.
The Johnson & Johnson ναccιnє is the only one of the three that requires just one shot to be effective. The others require two shots spaced apart.
In response to the Times report, Johnson & Johnson acknowledged in a statement that the "quality control process identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions," noting that the doses never advanced to the packaging stage.
"The issue was identified and addressed with Emergent and shared with the United States Food & Drug Administration [FDA]," the company added.
The company said it is sending additional experts to the facility to oversee manufacturing.